Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of drug interactions between leriglitazone, gemfibrozil, itraconazole, and carbamazepine and food effects in healthy male volunteers for adrenoleukodystrophy treatment

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial aims to study the effects of various medications when taken together with leriglitazone, an investigational drug, in healthy male subjects. The study will also examine how food affects the way leriglitazone works in the body. The trial involves testing interactions between leriglitazone and three different medicines: gemfibrozil (a medication used to lower blood fats), itraconazole (an antifungal medication), and carbamazepine (a medication used to treat epilepsy and nerve pain).

The study consists of four parts. In the first three parts, participants will receive leriglitazone along with one of the three mentioned medications to see how they interact. In the fourth part, researchers will study how taking leriglitazone with a high-fat meal affects the way the body processes the medication. The medication will be given as an oral suspension, which means it is a liquid form that can be swallowed.

Throughout the study, researchers will monitor participants' health through various tests, including blood samples to measure medication levels in the body, heart recordings (electrocardiograms), vital signs, and laboratory tests. They will also look at specific genes that might affect how the body processes these medications. The study is designed to understand how these different factors might change the way leriglitazone works in the body.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Study initiation

    The study is divided into four parts (A, B, C, and D), focusing on how leriglitazone interacts with other medications and food

    You will need to avoid alcohol, caffeine, and foods containing methylxanthine (such as coffee, tea, cola, chocolate, energy drinks) for 3 days before entering the clinical research center and during your stay

  2. Step 2

    Part A - Interaction with gemfibrozil

    You will receive leriglitazone orally (by mouth) as a single dose

    You will also receive gemfibrozil tablets (600 mg) orally

    Blood samples will be collected to measure how these medications interact in your body

  3. Step 3

    Part B - Interaction with itraconazole

    You will receive leriglitazone orally as a single dose

    You will also receive itraconazole capsules (100 mg) orally

    Blood samples will be collected to measure how these medications interact in your body

  4. Step 4

    Part C - Interaction with carbamazepine

    You will receive leriglitazone orally as a single dose

    You will also receive carbamazepine tablets (200-300 mg) orally

    Blood samples will be collected to measure how these medications interact in your body

  5. Step 5

    Part D - Food effect study

    You will receive leriglitazone orally as a single dose

    The medication will be taken with a high-fat breakfast to study how food affects the medication absorption

    Blood samples will be collected to measure how food affects the medication in your body

  6. Step 6

    Safety monitoring

    Throughout the study, you will undergo regular safety checks including:

    Heart monitoring (electrocardiograms)

    Vital signs measurements

    Laboratory safety tests

    Monitoring for any side effects

Who can join the trial?

12 criteria

  • Must be a healthy male between 18 and 50 years old
  • Body Mass Index (BMI) must be between 18 and 30 kg/m² (BMI is a measure that uses your height and weight to determine if your weight is healthy)
  • Must be able and willing to provide informed consent (agreement to participate after understanding study details)
  • Male participants with female partners who can become pregnant must either:
    • Avoid sexual intercourse, or
    • Use a condom and ensure their partner uses highly effective birth control (with less than 1% failure rate) for at least 90 days after the last study treatment
    • Must not donate sperm for at least 12 weeks after the last study treatment
    • Must have no significant medical conditions based on:
      • Medical history review
      • Physical examination
      • Laboratory test results
      • Must be willing to avoid:
        • Alcohol
        • Caffeine
        • Foods and drinks containing methylxanthine (such as coffee, tea, cola, chocolate, energy drinks) for 3 days before and during the study center stay

Who cannot join the trial?

15 criteria

  • History of any significant medical conditions, including but not limited to heart, liver, kidney, nervous system, or mental health disorders
  • Current use of medications that could interact with the study drug (except those specified in the study)
  • Female participants (study is limited to male participants only)
  • Age below 18 or above 55 years
  • Body Mass Index (BMI) outside the range of 18.5-30 kg/m² (BMI is a measure of body fat based on height and weight)
  • Abnormal blood pressure readings or irregular heart rhythm
  • History of drug or alcohol abuse within the past 2 years
  • Participation in other clinical trials within the past 30 days
  • Known allergies to any medications similar to the study drug
  • Smoking or use of nicotine products within 3 months before the study
  • Significant abnormal findings in laboratory tests, including blood and urine tests
  • Unable to follow study procedures or provide informed consent
  • History of severe allergic reactions to any medications
  • Regular consumption of more than 2 alcoholic drinks per day
  • Use of herbal supplements or vitamins within 7 days before the study
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Leriglitazone

    is an investigational medication being studied for its interaction with other drugs and food effects. It is given orally.

  • Gemfibrozil

    is a medication commonly used to lower high triglyceride and cholesterol levels in the blood. It belongs to a group of drugs called fibrates.

  • Itraconazole

    is an antifungal medication used to treat various fungal infections. It works by stopping the growth of fungi that cause infections.

  • Carbamazepine

    is an anticonvulsant and mood-stabilizing medication primarily used to treat epilepsy and neuropathic pain. It is also sometimes prescribed for bipolar disorder.

What is already known about the treatment

  • Leriglitazone

    An oral medication currently being investigated in clinical trials for the treatment of Adrenoleukodystrophy, a rare genetic disorder affecting the nervous system. This drug belongs to the class of PPAR (peroxisome proliferator-activated receptor) agonists and is being studied for its interaction with other medications such as gemfibrozil, itraconazole, and carbamazepine. The medication is taken by mouth and its absorption characteristics with food are being evaluated in clinical trials.

  • Gemfibrozil

    A lipid-lowering medication taken orally that belongs to the fibrate class of drugs, commonly used to reduce triglycerides and increase good cholesterol levels in the blood. It works by activating certain proteins that break down fats in the body and is often studied in drug interaction trials due to its effects on various metabolic pathways.

  • Itraconazole

    An oral antifungal medication used to treat various types of fungal infections, belonging to the azole class of antifungal drugs. It works by preventing the formation of fungal cell membranes and is frequently used in drug interaction studies because it can affect how other medications are processed by the body.

  • Carbamazepine

    An oral anticonvulsant medication primarily used to treat epilepsy and neuropathic pain, which works by decreasing abnormal electrical activity in the brain. It belongs to the dibenzazepine family of drugs and is often included in drug interaction studies as it can affect the metabolism of other medications in the body.

Investigated diseases

Adrenoleukodystrophy - A rare genetic condition that causes damage to the protective covering (myelin sheath) of nerve cells in the brain and spinal cord. The disease primarily affects males and is characterized by the buildup of very long-chain fatty acids in the body. It typically begins in childhood with symptoms that can include behavioral changes, vision problems, difficulty with walking and coordination. The condition progresses to affect hearing, speech, and muscle movement. The disease can occur in several forms, with varying ages of onset and patterns of progression.
Trial detailsLast updated 30 Oct 2026
Age18+ yearsPhasePhase ITrial ID2025-521508-23-00Protocol codeMT-1-02Estimated enrolment73 patientsSponsorMinoryx Therapeutics S.L.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.